drug
lenvatinib
updated 3mo agoby Cancer Institute and Hospital Chinese Academy of Medical Sciences
community read0 votes
🐶 often sniffed alongside
top 8- tagOncology20 co-mentions · 3 sources
- companyEisai Co Ltd2 co-mentions · 2 sources
- tagInfectious Disease2 co-mentions · 2 sources
- tagBreast Cancer2 co-mentions · 2 sources
- tagColorectal Cancer2 co-mentions · 2 sources
- tagMelanoma2 co-mentions · 2 sources
- druglenvatinib mesylate2 co-mentions · 2 sources
- companyCancer Institute and Hospital Chinese Academy of Medical Sciences1 co-mentions · 1 sources
all catalysts(1)
Trials studying lenvatinib
- phase3A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
- EP1Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
- phase2Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
- phase3Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- phase3Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- phase2HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
- phase2STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
- phase3Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
News(1)
- Biomarker-Driven Treatment Decisions and Managing Progression After Frontline ImmunotherapyUpfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.onclive · 3mo ago
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that